ANTI TUBERCULAR THERAPY related ocular diseases
Reading File
Finding Sources
Finding Sources
Searching PubMed
ethambutol AND optic neuropathy
Searching the Web
WHO operational handbook tuberculosis ethambutol optic neuritis visual acuity monitoring
Reading File
Reading File
Reading File
Reading Article
PMID: 41905405
Ocular adverse effects of anti-tubercular therapy (ATT)
The most important ocular toxicity of ATT is toxic optic neuropathy due to ethambutol. In a patient receiving ATT who develops visual symptoms, first distinguish drug toxicity from ocular tuberculosis, diabetes, nutritional optic neuropathy, or another optic nerve disorder.
| Drug | Main ocular adverse effect | Key features |
|---|---|---|
| Ethambutol | Optic neuritis / toxic optic neuropathy | Most important and most common ATT-related ocular toxicity. Usually bilateral, painless, progressive visual loss. |
| Isoniazid (INH) | Rare toxic optic neuropathy | Risk rises when used concurrently with ethambutol. |
| Rifampicin | Rare ocular hypersensitivity | Conjunctivitis, red eye, lacrimation, periocular edema, occasionally uveitis-like inflammation, particularly with intermittent use. |
| Clofazimine | Pigmentation | Brown-red discoloration of conjunctiva and skin; may cause corneal/conjunctival deposits. Usually cosmetic. |
| Linezolid (drug-resistant TB regimens) | Optic neuropathy | Usually with prolonged treatment; may be associated with peripheral neuropathy. |
| Ethionamide / prothionamide | Rare optic neuritis | Uncommon, but reported. |
1. Ethambutol-induced optic neuropathy
Mechanism: Toxic injury to the optic nerve, probably involving retinal ganglion-cell/mitochondrial function. It is dose- and duration-related and is more likely with impaired renal clearance.
Typical onset
- Commonly after 3 to 6 months, but may occur earlier.
- Risk is low with standard weight-based dosing, but increases with high dose, long treatment, renal impairment, and older age. Kanski notes that toxicity is rare at 15 mg/kg/day and recommends not exceeding this daily dose. Kanski's Clinical Ophthalmology, p. 920.
Symptoms
- Painless, bilateral, usually symmetrical blurring of vision
- Reduced central vision
- Difficulty recognizing colors, classically red-green dyschromatopsia
- Reduced contrast sensitivity
- Central, centrocecal, paracentral, or occasionally peripheral visual-field defects
Signs
- Reduced visual acuity
- Impaired color vision, often an early sign
- Central scotoma on visual-field testing
- Optic disc may initially be normal, mildly swollen, or later become pale due to optic atrophy
- Pupillary responses can be normal in symmetric bilateral disease
Harrison's describes reduced visual acuity, central scotoma, and loss of green color perception as typical features. Harrison's Principles of Internal Medicine, 22nd ed.
Risk factors
- Higher ethambutol dose
- Longer duration of therapy
- Renal impairment
- Elderly age
- Pre-existing optic nerve disease or poor baseline vision
- Concomitant isoniazid
A recent systematic review found the most consistent associations with ethambutol optic neuropathy were longer treatment duration and renal disease, although certainty of the underlying evidence was low. 2026 systematic review
2. Screening and monitoring for ethambutol
Before starting ethambutol, document:
- Visual acuity in each eye
- Color vision, for example Ishihara plates
- Visual fields when feasible
- Fundus/optic-disc examination
During therapy:
- Ask at each visit about blurred vision, color desaturation, and difficulty reading.
- Repeat visual acuity and color assessment regularly, especially in patients with renal disease, prolonged treatment, high doses, or unreliable symptom reporting.
- Patients should report new visual symptoms urgently.
Harrison's recommends baseline visual acuity, visual fields, color testing, and optic-fundus examination, followed by periodic monitoring. The WHO also advises prompt omission of ethambutol if optic neuritis is diagnosed. WHO handbook guidance
3. Management of suspected ATT optic neuropathy
- Stop ethambutol immediately in consultation with the TB clinician. Do not wait for severe visual loss.
- Obtain urgent ophthalmology assessment:
- Best-corrected visual acuity
- Color vision
- Visual fields
- Fundus examination
- OCT retinal nerve fiber/ganglion-cell assessment, if available
- Review renal function, dose, duration, and other neurotoxic drugs.
- Consider whether isoniazid or another neurotoxic agent should also be stopped or substituted.
- Modify the TB regimen using culture/susceptibility results and TB-specialist advice.
Visual recovery often begins after cessation and may take months. However, delayed recognition can result in incomplete recovery or permanent optic atrophy. Kanski's Clinical Ophthalmology, p. 920.
Exam pearl
A patient on ATT with painless bilateral loss of vision, central scotoma, and red-green color defect has ethambutol-induced toxic optic neuropathy until proven otherwise.
This is a shared conversation. Sign in to Orris to start your own chat.